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ABSTRACT 
Background: Leptin resistance, which may develop during the aging process, stimulates the 
production of proinflammatory cytokines and insulin resistance that could impair the muscle function. 
However, the role of leptin on physical functioning among older adults has not yet been elucidated. 
Objective: To examine the association between serum leptin levels and physical function impairment 
in older adults. 
Design and setting: Prospective study of 1,556 individuals aged ≥60 years from the Seniors-ENRICA 
cohort, who were free of physical function limitation at baseline.  
Main outcome measure: Serum leptin was measured in 2008-2010, and incident functional limitation 
was assessed through 2012. Self-reported limitations in agility and mobility were assessed with the 
Rosow and Breslau scale, limitation in the lower extremity function was measured with the Short 
Physical Performance Battery, and impairment in the overall physical performance with the physical 
component summary of the SF-12.  
Results: After adjustment for potential confounders, and compared to individuals in the lowest quartile 
of leptin concentration, those in the highest quartile showed increased risk of impaired physical 
function; the odds ratio (95% confidence interval) and p-trend was: 1.95 (1.11-3.43), p=0.006 for self-
reported impaired mobility; 1.76 (1.08-2.87), p=0.02 for self-reported impaired agility; 1.48 (1.02-
2.15), p=0.04 for limitation in the lower extremity function; and 1.97 (1.20-3.22), p=0.01 for 
decreased overall physical performance. These associations were only modestly explained by C-
reactive protein and insulin resistance. Moreover, the associations held across groups with varying 
health status and were independent of estimated total body fat. 
Conclusions: Higher leptin concentration was associated with increased risk of impaired physical 
function. Preserving metabolic function during the old age could help delaying physical function 
decline.  
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INTRODUCTION 
Life expectancy has rapidly increased in the last decades, but healthy life expectancy has grown more 
slowly [1,2]. Healthy ageing is a process which enables older people to take an active part in society 
and to enjoy an independent and high quality of life [3]. A well-known threat to healthy ageing is the 
impairment of physical functioning. Unfortunately, the understanding of the biological factors that 
lead to impaired physical function in the old age is still limited [4]. 
There is evidence of the detrimental effect of obesity on physical function in older adults [5,6,7,8,9]. 
In other studies, underweight has also been associated with functional decline [10]. A plausible 
explanation is that adiposity, in addition to body weight, has a pivotal role on physical functioning 
[11]. In fact, older adults with sarcopenia or obesity are at higher risk of impaired physical function 
[12] probably because fat infiltrated in the muscle induces oxidative stress and chronic inflammation, 
which at the same time decreases skeletal muscle mass and strength [13,14]. Furthermore, other long 
term effects of adiposity, such as insulin resistance, could also have an impact on physical function 
[15]. However, the association between sarcopenic obesity and impairment in physical functioning has 
only been modestly explained by C-reactive protein (CRP) and insulin sensitivity [12], suggesting that 
other metabolic factors could be involved, such as adipokines. 
Leptin is the first adipokine discovered and one of the best characterized. It is mainly secreted by the 
white adipocyte tissue and it acts predominantly through the central nervous system, contributing to 
the regulation of appetite and several neuroendocrine pathways, like glucose homeostasis [16]. But 
leptin has also peripheral effects, some of which are associated with the production of 
proinflammatory cytokines and insulin resistance [17]. Obese subjects can develop a state of central 
leptin resistance followed by increased serum leptin levels. In this state, the peripheral effects of leptin 
could prevail over its central action [18]. It has been suggested that leptin resistance could develop 
with the aging process [13]. In fact, one prospective study among middle-aged women has recently 
found that higher leptin concentration predicts impairments in mobility [19]. Nevertheless, its role on 
physical functioning among older adults has not yet been elucidated, specially whether or not is 
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mediated by inflammation or insulin resistance. Thus, we hypothesize that the increase in serum leptin 
levels associated with ageing could lead to functional limitations. Thus, the aim of this study was to 
examine the prospective association between serum leptin levels and the incident impairment of 
physical function among older adults. 
 
METHODS 
Study design and participants 
Baseline data for this prospective study were obtained from the ENRICA cohort, which was 
established in 2008-2010 and involved 12,948 individuals representative of the non-institutionalized 
adult population of Spain [20]. At baseline, information on sociodemographic characteristics, lifestyle, 
health status and morbidity was collected through a telephone interview. In two subsequent home 
visits, trained research staff also obtained dietary information, conducted a physical examination and 
obtained blood and urine samples for several biochemical and hormonal determinations. In 2012, we 
performed a second wave of data collection among the participants aged 60 and older (n=2,614), 
which comprise the Senior-ENRICA cohort; given that 95 (3.6%) individuals passed-away during the 
follow-up period, updated information was obtained only for the remaining 2,519 subjects. The 
Clinical Research Ethics Committee of the ‘La Paz’ University Hospital approved the study protocol. 
All study participants gave written informed consent. 
Study variables 
Leptin and other biomarkers 
Baseline serum leptin concentration (ng/mL) was determined by enzyme-linked immunoassay 
(Diagnosis Biochem Canada) using a BEST2000 robot. The sensitivity of this test was 0.5 ng/dL and 
the coefficients of variation intra- and inter-assay were 7.5 and 9.6%, respectively. We also measured 
levels of insulin resistance and inflammation because they could be associated with leptin 
concentration. The homeostatic model assessment for insulin resistance index (HOMA-IR) was 
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calculated by multiplying glucose by insulin and dividing by 405. Glucose (mg/dL) was measured by 
the glucose oxidase method, and insulin (µU/mL) by immunoradiometric assay. Finally, CRP (mg/L) 
was determined by latex-enhanced nephelometry. The coefficients of variation intra- and inter-assay 
were <4% and <4% for glucose, 5.2 and 6.9% for insulin and 3.2 and 5.9% for CRP. 
Physical function 
We considered three basic domains of physical function: self-reported agility and mobility and an 
objective measure of lower extremity function, as well as a measure of overall self-reported physical 
performance. Limitation in self-reported agility was defined by answering “a lot” to the following 
question from the Rosow and Breslau scale [21]: “On an average day with your current health, would 
you be limited in bending and kneeling?”; whose categories of response were “yes, a lot”, “yes, a 
little” and “not at all”. In the same way, limitation in self-reported mobility was defined by answering 
“a lot” to any of the following questions from the Rosow and Breslau scale [21]: “On an average day 
with your current health, would you be limited in the following activities: 1) picking up or carrying a 
shopping bag?; 2) climbing one flight of stairs?; 3) walking several city blocks (a few hundred 
meters)?”. Limitation in the lower extremity function was assessed using the Short Physical 
Performance Battery (SPPB). The SPPB combines the results of three measurements: the gait speed 
across 2.44 meters, balance using three hierarchical tandem tests, and the ability to rise from a chair 
five times consecutively [22]. The score with the sum of these three components ranges from 0 to 12 
(highest level of function). Participants were considered to have limited function when they scored ≤9 
points in the SPPB; of note is that this test was only measured in 2012. Lastly, limitation in self-
reported overall physical performance was deemed to exist when the score of the physical component 
summary (PCS) of the 12-Item Short-Form Health Survey (SF-12) decreased at least 10 points from 
baseline to follow-up. We used this cut-off point because a 10-point lower score has been associated 
with severe adverse health outcomes [23,24]. Moreover, in medical practice, a 10-point change in 
individual patients is considered as a clinically relevant alarm signal [25]. 
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Other variables 
We also collected data on several potential confounders of the study association. These included 
sociodemographic variables and health behaviors such as age, sex, educational level, tobacco smoking, 
alcohol intake, time spent watching TV and physical activity during leisure time (using the EPIC-
Spain validated questionnaire) [26]. Additionally, we considered two dietary variables derived from a 
validated diet history [27]: adherence to the Mediterranean diet, according to the Trichopoulou index 
[28], and total energy intake. Regarding adiposity, we estimated the percentage (%) of body fat using 
the CUN-BAE equation, which is based on sex, age, weight and height [29]. Finally, we obtained 
information on morbidity. Blood pressure was measured under standardized conditions and 
hypertension was defined as having a systolic blood pressure ≥140 mm Hg, or diastolic blood pressure 
≥90 mm Hg, or being under drug treatment. Being diabetic was defined as having a medical diagnosis, 
or fasting serum glucose ≥126 mg/dl, or being treated with insulin or other hypoglycemic agents. 
Individuals also reported whether they had been diagnosed with cardiovascular disease, chronic 
obstructive pulmonary disease, cancer at any site, osteomuscular disease (including osteoarthritis, 
arthritis and hip fracture) or depression requiring pharmacological treatment. Moreover, cognitive 
function was measured using the Mini-Mental State Examination (MMSE), defining cognitive 
impairment as a MMSE score of <23 [30]. Finally, the Lawton-Brody index was used to ascertain 
limitations in instrumental activities of daily living (IADL) [31]. 
Data analysis 
Of the sample comprising 2,519 individuals, we excluded 24 subjects with baseline medical diagnosis 
of dementia, Alzheimer or Parkinson disease. We excluded 658 participants who lacked data on 
mobility (n=184), agility (n=3), SPPB (n=447) or PCS score (n=24), 6 individuals without leptin 
determination, and 54 with missing data on potential confounders. Additionally, we excluded the 
participants with basal limitations in physical functioning: 91 with self-reported impaired mobility, 75 
with self-reported impaired agility and 55 with fatigue, as a proxy of overall limitation in physical 
functioning. Baseline fatigue was measured by asking respondents how much time during the past 4 
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weeks they felt tired; responses of “all of the time” or “most of the time” were considered positive 
[32]. Thus, the analyses were conducted with 1,556 individuals. 
Logistic regression models were used to estimate the odds ratios (OR) and the 95% confidence 
interval (CI) of the association between the serum concentration of leptin and incident limitation in 
physical function. Given that leptin concentration did not follow a normal distribution, we used the 
log-transformed values. Participants were classified into sex-specific quartiles, because leptin 
concentration was significantly higher in women (30.9 ng/dL ±18.9) than in men (12.3 ng/dL ±9.5). 
Several regression models and sensitivity analyses were built (please see a detailed description in 
Appendix 1). Moreover, to summarize the study associations we repeated all the analyses using an 
increment of one standard deviation (SD) of leptin concentration as the independent variable. We 
tested if the main results varied with sex by using interaction terms. Since the results were similar in 
each sex and the interactions did not reach statistical significance, the results are reported for the total 
study sample. Statistical analyses were performed with the STATA software (version 13.0; Stata 
Corp., College Station). A 2-tailed p<0.05 was considered statistically significant. 
 
RESULTS 
During a mean follow-up period of 3.5 years, the incidence of limitations in mobility was 12.5%, in 
agility 20.4% and in overall physical performance 16.7%. Furthermore, 54.8% of the individuals had 
impaired lower extremity function at the end of follow-up. Table 1 shows the socio-demographic, 
behavioral and clinical characteristics of the participants at baseline, according to categories of 
functional impairment. With regards to leptin, the mean ± standard deviation of serum concentration 
was 21.2±17.5 ng/mL, and it was significantly higher among subjects with any incident functional 
impairment.  
Compared to individuals in the lowest quartile of leptin concentration, those in the highest quartile 
showed increased risk of impaired physical function; in model 3, the ORs (95% CI) and p-trend were: 
1.95 (1.11-3.43), p=0.006 for self-reported impaired mobility, 1.76 (1.08-2.87), p=0.02 for self-
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reported impaired agility, 1.48 (1.02-2.15), p=0.04 for lower extremity function, and 1.97 (1.20-3.22), 
p=0.01 for decreased overall physical performance (Table 2). The additional adjustment for CRP and 
HOMA-IR only modestly reduced the association found. Moreover, analyses using the increment of 
one SD of leptin instead of the quartiles of the concentration gave similar statistically significant 
results (Table 2). Additional adjustment for length of follow-up did not materially change the results 
(data not shown). 
Table 3 shows the association between leptin concentration and impairment in physical function 
among subgroups of participants with better health status. Per each increment of one SD of leptin 
concentration, we observed a higher incidence of limitations in all the domains, especially in self-
reported impaired mobility, with a range of 55-62% of risk increment, followed by a 22-41% for 
impaired overall physical performance, 21-38% for self-reported impaired agility, and 10-18% for 
impaired lower extremity function. In stratified analyses, the association between leptin concentration 
and the impairment of physical function was statistically significant only among individuals with less 
physical activity, more hours watching TV and higher % body fat (please see Appendix 2). 
Nevertheless, the study association did not significantly vary across the strata (p for interaction >0.08 
in all cases). 
 
DISCUSSION 
In this prospective study of community-dwelling older adults, higher serum leptin concentration was 
associated with greater risk of impairment in mobility, agility, lower extremity function and overall 
physical performance. These associations were observed in groups with varying health behaviors and 
status and were independent of the estimated body fat, which suggests that the impact of leptin on 
physical function is not totally explained by adiposity.  
Several studies have found that body composition plays a role in the age-associated decline of physical 
function and the occurrence of frailty in older adults [5,6,7,8,9,10,14]. This could be due to several 
closely-related mechanisms. First, a sedentary lifestyle may contribute to muscle weakness and 
11 
 
atrophy, with muscle being progressively infiltrated by fat tissue. In turn, impaired physical function 
may lead to greater sedentariness. Moreover, excess adiposity induces inflammation and metabolic 
dysfunction, which also contribute to reduce muscle quality. These factors could partially explain the 
clustering  of various  body phenotypes, such as obesity and sarcopenia, which leads to sarcopenic 
obesity [12]. On the other hand, there is evidence that weight loss in older adults predicts disability 
[33], especially among those who were obese at entering old age [34].  
Leptin contributes to energy balance mostly by reducing food intake and increasing energy 
expenditure, and it also has a role in vascular function and in the regulation of serum glucose and 
insulin [35,36]. However, in obese and older people, high leptin levels may reflect a state of 
resistance, in which vascular function and insulin sensitivity are altered. Moreover, given that leptin 
concentration reflects the metabolic activity of body fat, the mechanisms for the association between 
leptin and functional limitations could also entail an increased energy demand due to excess body fat 
and the subsequent metabolic dysfunction. In addition, leptin is a proinflammatory adipokine. Thus, 
given that higher leptin is associated with higher risk of cardiovascular disease and diabetes [37,38], 
which are both linked to impaired physical function, we adjusted the analyses for cardiovascular 
disease and diabetes. The fact that the results held after adjustment, and that they were also observed 
among individuals free of these diseases, suggests that other mechanisms may account for the leptin-
functional impairment association. Moreover, our results also held after adjustment for CRP and 
HOMA-IR, which were used as a nonspecific proxy of the inflammation process and insulin 
resistance, respectively. Both conditions have often been related to functional impairment, but our 
findings suggest that leptin could be a prior step of the causal pathway. 
Our results concur with those of Karvonen-Gutierrez et al [19] showing that leptin concentration 
predicts poorer physical functioning. These are the first investigations to report an association between 
leptin and physical function, thought their study was conducted among middle-aged women and ours 
among older men and women. Specifically, in the study of Karvonen-Gutierrez et al [19], leptin was 
prospectively associated with longer stair climb, sit-to-rise and 2-pound lift times, and shorter reach 
distance. Contrary to our findings, Karvonen-Gutierrez et al did not observe an association between 
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leptin and worse results in the walking test or leg strength; although leptin has deleterious effects on 
muscle [39], a lack of an association in their study might be due to including younger individuals. Our 
results are of particular importance for the older population because they showed an association of 
leptin with lower extremity performance, which is a good predictor of disability, hospitalization and 
mortality [22].  
Our study has several strengths, including the relatively large sample size and the fact that most 
variables, including leptin and the components of physical functioning, were ascertained using 
standardized and validated methods. Also, the analyses were adjusted for a good number of well-
measured confounders, and the results were robust in several sensitivity analyses. The main limitation 
was the lack of measurement of the soluble receptor of leptin, which has shown a stronger relation 
than leptin with some health outcomes. Also, we did not measure other adipokines of potential 
interest, such as adiponectin [19]; however, we attempted to partially account for this limitation by 
adjusting the analyses for our estimation of subjects’ body fat, as a proxy for adipokines secretion, 
although the use of an objective measure of % body fat would have been desirable. We also lacked 
data about lean mass, which would have allowed us to characterize those individuals with sarcopenic 
obesity. Another limitation was the use of self-reported information as a proxy for mobility, agility 
and overall physical performance; however, we combined it with an objective assessment of lower 
extremity function, to achieve a more complete measurement of impaired physical function. 
Moreover, functional impairment was evaluated at the end of the follow-up, so that temporality and 
development of impairments during the interval period could not be fully ascertained. Finally, as in 
most observational studies, certain residual confounding cannot be ruled out, despite adjustment for 
many variables. 
 
CONCLUSION 
In conclusion, in community-dwelling older men and women, we found a significant association 
between higher leptin concentration and an increased risk of impaired physical function, which was 
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independent of the estimated body fat. The mechanisms of this association should be elucidated, but 
preserving metabolic function during the old age could help to delay physical function decline and 
subsequent disability.  
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Table 1. Participants’ characteristics at baseline according to physical function impairment (N=1,556) 
 Self-reported impaired mobility  Self-reported impaired agility  SPPB score ≤ 9 points  10-point decrease in PCS 
 No Yes  No Yes  No Yes  No Yes 
Participants, n  1,361 195  1,239 317  703 853  1,296 260 
Leptin, ng/mL 19.6 (15.7) 32.2 (24.1)c  18.9 (15.3) 30.1 (22.1)c  20.4 (16.7) 25.1 (20.5)c  18.1 (14.4) 23.8 (19.2)c 
Age, y 67.7 (5.8) 70.1 (6.4)c  67.6 (5.8) 69.7 (6.4)c  66.3 (5.2) 69.4 (6.2)c  67.8 (5.8) 68.9 (6.4)b 
Men, % 55.7 28.7c  57.6 31.6c  59.7 46.2c  53.2 48.1 
Primary education, % 47.8 65.1c  45.2 68.5c  42.1 56.4c  48.1 59.2b 
Current smoker, % 12.5 11.8b  12.8 11.0c  13.8 11.3  12.7 10.8 
Heavy drinker, % 9.3 5.1 b  9.2 7.3a  11.2 6.8c  9.0 7.7 
Physical activity, MET-h/wk 23.5 (15.6) 18.8 (13.6)c  24.0 (15.8) 18.5 (13.1)c  24.8 (15.8) 21.3 (15.0)c  23.1 (15.6) 21.7 (14.5) 
TV watching, h/wk 16.9 (10.4) 20.2 (11.4)c  16.5 (10.1) 20.3 (11.9)c  16.3 (10.3) 18.1 (10.9)b  17.0 (10.3) 18.8 (12.2)a 
Trichopoulou index score 4.6 (1.5) 4.3 (1.6)a  4.6 (1.5) 4.4 (1.6)a  4.7 (1.5) 4.4 (1.5)c  4.6 (1.5) 4.5 (1.6) 
Energy intake, kcal/d 2,121 (769) 1,892 (538)c  2,131 (784) 1,943 (564)c  2,165 (826) 2,032 (671)b  2,100 (750) 2,054 (735) 
Estimated body fat, % 35.7 (6.7) 40.6 (4.5)c  35.2 (6.5) 40.7 (7.0)c  35.0 (6.4) 37.4 (7.2)c  36.1 (6.9) 37.7 (6.9)b 
Morbidity, %            
 Diabetes 13.3 19.0a  13.0 18.0a  9.5 17.7c  13.9 16.6 
 Hypertension 63.9 66.2  63.8 65.9  61.6 66.4  63.4 68.1 
 Cardiovascular disease 3.2 7.2b  3.2 5.7a  3.1 4.1  3.6 4.2 
 Chronic lung disease 6.3 11.8b  5.7 12.3c  5.4 8.3a  6.2 11.2b 
 Cancer 1.6 2.1  1.5 2.2  1.4 1.9   1.5 2.3 
 Osteomuscular disease 39.5 71.8c  36.5 71.0c  36.9 48.9c  41.6 53.1b 
 Depression 5.7 12.3b  5.0 12.6c  4.6 8.2 b  5.6 11.5b 
Incident morbidity during 
follow-up, % 
24.0 36.4c  23.6 33.1b  21.9 28.5b  28.5b 35.0c 
IADL disability, % 6.2 14.9c  5.6 13.9c  4.8 9.2b  6.9 8.9 
MMSE score 28.3 (1.9) 27.1 (2.6)c  28.3 (1.8) 27.4 (2.5)c  28.4 (1.6) 27.9 (2.3)c  28.2 (1.9) 27.8 (2.3)b 
C-reactive protein*, mg/L 0.17 (1.03) 0.21 (1.10)a  0.17 (1,03) 0.22 (1.07)c  0.16 (1.04) 0.19 (1.04)b  0.17 (1.03) 0.20 (1.08)a 
HOMA-IR 2.3 (0.1) 3.1 (0.3)c  2.3  (2.1) 2.9 (2.7)c  2.4 (2.3) 2.4 (1.6)  2.3 (2.1) 2.6 (2.3)a 
PCS: Physical component summary of the SF-12; SPPB: Short physical performance battery; MET; Metabolic equivalent; MMSE: Mini-Mental State Examination. 
ap<0.05; bp<0.01; cp<0.001 
For continuous variables, the mean (standard deviation) is reported.  
*Geometric mean (standard error of the geometric mean).
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Table 2. Odds ratios (95% confidence interval) for the association between sex-specific quartiles of serum concentration of leptina and physical function 
impairment during a 3.5 year follow-up. (N=1,556) 
 Leptin concentration  Per 1 SD 
increase of 
leptin  
                 Quartile 1 
(n=394) 
Quartile 2 
(n=388) 
Quartile 3 
(n=391) 
Quartile 4 
(n=383) 
p-trend 
Self-reported impaired mobility       
 Cases 39 37 45 74   
 Model 1b 1.00 0.98 (0.61-1.60) 1.20 (0.76-1.91) 2.18 (1.42-3.34) <0.001 1.48 (1.30-1.70) 
 Model 2c 1.00 0.84 (0.50-1.42) 1.07 (0.65-1.76) 1.82 (1.13-2.93) 0.004 1.42 (1.22-1.66) 
 Model 3d 1.00 0.88 (0.51-1.51) 1.12 (0.65-1.92) 1.95 (1.11-3.43) 0.006 1.55 (1.30-1.85) 
 Model 4e 1.00 0.82 (0.47-1.43) 1.01 (0.57-1.80) 1.69 (0.92-3.13) 0.03 1.53 (1.27-1.85) 
Self-reported impaired agility       
 Cases 53 69 79 116   
 Model 1b 1.00 1.45 (0.97-2.16) 1.68 (1.14-2.49) 2.87 (1.97-4.18) <0.001 1.44 (1.28-1.62) 
 Model 2c 1.00 1.32 (0.85-2.04) 1.57 (1.02-2.40) 2.36 (1.55-3.59) <0.001 1.32 (1.16-1.61) 
 Model 3d 1.00 1.14 (0.73-1.80) 1.28 (0.80-2.02) 1.76 (1.08-2.87) 0.02 1.21 (1.04-1.42) 
 Model 4e 1.00 1.14 (0.71-1.81) 1.24 (0.76-2.03) 1.62 (0.95-2.76) 0.06 1.17 (1.00-1.39) 
SPPB score ≤ 9 points       
 Cases 201 202 204 246   
 Model 1b 1.00 1.08 (0.80-1.46) 1.03 (0.77-1.38) 1.67 (1.24-2.26) 0.001 1.22 (1.09-1.27) 
 Model 2c 1.00 1.02 (0.75-1.38) 0.95 (0.69-1.27)  1.36 (0.99-1.27) 0.05 1.13 (1.01-1.27) 
 Model 3d 1.00 1.05 (0.77-1.44) 1.00 (0.71-1.38) 1.48 (1.02-2.15) 0.04 1.18 (1.03-1.35) 
 Model 4e 1.00 1.04 (0.75-1.43) 1.00 (0.70-1.43) 1.48 (0.98-2.23) 0.11 1.18 (1.02-1.38) 
10-point decrease in PCSe       
 Cases 46 66 68 80   
 Model 1b 1.00 1.63 (1.08-2.46) 1.71 (1.13-2.57) 2.18 (1.46-3.26) 0.001 1.29 (1.14-1.46) 
 Model 2c 1.00 1.51 (0.98-2.32) 1.62 (1.06-2.48) 1.92 (1.25-2.94) 0.004 1.23 (1.08-1.41) 
 Model 3d 1.00 1.53 (0.98-2.37) 1.64 (1.04-2.57) 1.97 (1.20-3.22) 0.01 1.25 (1.07-1.46) 
 Model 4e 1.00 1.68 (1.06-2.64) 1.82 (1.12-2.94) 2.12 (1.24-3.62) 0.02 1.25 (1.06-1.48) 
PCS: Physical component summary of the SF-12; SPPB: Short physical performance battery 
aSex-specific quartile cut-off points for leptin levels were 5.5, 9.8 and 16.6 ng/mL in men and 18.0, 29.1 and 39.5 ng/mL in women.  
bModel 1: logistic regression model adjusted for sex and age (years). 
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cModel 2: model 1 additionally adjusted for educational level (≤primary, secondary, university), smoking behavior (never, former, current), alcohol consumption (none, moderate, heavy 
drinker), leisure-time physical activity (quartiles of MET-h/wk), TV watching (tertiles of h/d), Mediterranean diet score (tertiles), energy intake (quartiles of Kcal/d), diabetes, hypertension, 
cardiovascular disease, cancer, chronic lung disease, osteomuscular disease, depression, incident chronic disease during follow-up, and MMSE score (quartiles). 
dModel 3: model 2 additionally adjusted for % body fat (quartiles). 
eModel 4: model 3 additionally adjusted for C-reactive protein (quartiles) and HOMA-IR (quartiles). 
eAdditionally adjusted for basal PCS. 
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Table 3. Odds ratios (95% confidence interval)a of physical function impairment during a 3.5 year follow-up per 1 SD increase of serum concentration of 
leptin among subgroups of participants with better health status. 
                 Self-reported 
impaired mobility 
Self-reported 
impaired agility 
SPPB score ≤ 9 
points 
10-point decrease in 
PCSb 
No basal diabetes (n=1,338)     
 Cases 158 260 222 702 
 OR (95 % CI) 1.55 (1.27-1.89) 1.27 (1.07-1.51) 1.24 (1.04-1.47) 1.18 (1.02-1.37) 
No basal osteomuscular disease (n=879)     
 Cases 55 92 122 436 
 OR (95 % CI) 1.62 (1.20-2.21) 1.38 (1.06-1.78) 1.41 (1.11-1.78) 1.10 (0.92-1.32) 
No basal IADL disability (n=1,443)     
 Cases 166 273 237 774 
 Model 2 1.56 (1.29-1.89) 1.23 (1.05-1.45) 1.22 (1.04-1.44) 1.16 (1.01-1.34) 
No incident cognitive impairment 
(n=1,524) 
    
 Cases 183 299 249 825 
 OR (95 % CI) 1.55 (1.29-1.85) 1.21 (1.03-1.42) 1.23 (1.04-1.43) 1.18 (1.03-1.36) 
No incident morbidity (n=1,159)     
 Cases 124 212 169 610 
 OR (95 % CI) 1.60 (1.26-2.03) 1.21 (1.00-1.47) 1.24 (1.01-1.52) 1.17 (1.01-1.38) 
IADL: Instrumental activities of daily living; PCS: Physical component summary of the SF-12; SPPB: Short physical performance battery. OR: odds ratio; CI: Confidence interval. 
aAnalyses adjusted as model 2 in table 2. 
bAdditionally adjusted for basal PCS. 
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Supplementary data. Appendix 1 
Data analysis 
The first regression model was adjusted for sex and age (years). The second model was 
additionally adjusted for educational level (primary or less, secondary or university), smoking 
(never, former or current), alcohol consumption (abstainer, moderate, or heavy drinker, with the 
threshold between moderate and heavy drinking established as 20 g/d in men and 10 g/d in 
women), TV watching (tertiles of h/d), leisure physical activity (quartiles of METs-h/week), 
adherence to Mediterranean diet (tertiles of the score), energy intake (quartiles of kcal/day), 
hypertension, diabetes, cardiovascular disease, chronic obstructive lung disease, cancer, 
osteomuscular disease, depression, incident morbidity between 2008 and 2012, and cognitive 
function (quartiles of MMSE score). The third model was additionally adjusted for the 
estimation of % body fat (quartiles), as a proxy for the concentration of adipokines other than 
leptin, and a fourth model was also adjusted for HOMA-IR and CRP (modeled in quartiles) to 
assess if these biomarkers could partially explain the association between leptin and functional 
impairment. We additionally included the length of follow-up as a covariate in a fifth model. 
Moreover, analyses regarding changes in PCS score were also adjusted for the basal PCS. To 
investigate the linear dose-response relationship, we estimated the p for trend by modeling 
leptin as a continuous variable. 
Additionally, we performed some sensitivity analyses by excluding participants with diabetes, 
osteomuscular disease, IADL limitation, and cognitive impairment at baseline or with incident 
morbidity during the follow-up. Moreover, because the physiology of leptin may differ 
according to body adiposity and physical activity [16], we conducted analyses stratified by the 
median of % body fat, METs-h/d in leisure activity and hours of TV watching. To assess if the 
study association varied across the strata we built interaction terms as the product of leptin 
quartiles by the stratification variables, and then used the likelihood ratio test to compare 
models with and without interaction terms. 
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Supplementary data. Appendix 2 
 
Table Appendix 2. Odds ratios (95% confidence interval)a of physical function impairment during a 3.5 year follow-up per 1 SD increase of serum 
concentration of leptin, stratified by physical activity, time spent watching TV and % body fat. 
                  Self-reported 
impaired mobility 
Self-reported 
impaired agility 
SPPB score ≤ 9 
points 
10-point decrease 
in PCSb 
Physical activity ≥ median (n=766)     
 Cases 74 124 122 384 
 OR (95 % CI) 1.37 (1.02-1.86) 1.05 (0.81-1.34) 1.13 (0.89-1.46) 1.27 (1.02-1.58) 
Physical activity < median (n=790)     
 Cases 121 193 138 469 
 OR (95 % CI) 1.78 (1.40-2.27) 1.32 (1.07-1.64) 1.35 (1.09- 1.69) 1.12 (0.93-1.35) 
P-interaction 0.15 0.48 0.84 0.25 
     
TV watching < median (n=850)     
 Cases 86 141 134 427 
 OR (95 % CI) 1.46 (1.10-194) 1.24 (0.97-1.59) 1.21 (0.96-1.53) 1.08 (0.90-1.30) 
TV watching ≥ median (n=706)     
 Cases 109 176 126 426 
 OR (95 % CI) 1.55 (1.23-2.01) 1.24 (1.01-1.53) 1.29 (1.03-1.61) 1.32 (1.06-1.63) 
P-interaction 0.59 0.75 0.12 0.75 
     
% Body fat < median (n=778)     
 Cases 58 91 116 371 
 OR (95 % CI) 1.35 (0.91-2.02) 1.17 (0.85-1.62) 1.25 (0.95-1.65) 1.05 (0.85-1.30) 
% Body fat ≥ median (n=778)     
 Cases 137 226 144 482 
 OR (95 % CI) 1.58 (1.28-1.96) 1.22 (1.01-1.47) 1.26 (1.03-1.53) 1.25 (1.03-1.51) 
 P-interaction 0.65 0.71 0.78 0.08 
PCS: Physical component summary of SF-12; SPPB: short physical performance battery; OR: Odds ratio; CI: Confidence interval. 
a Analyses adjusted as model 2 in table 2 
b Additionally adjusted for basal PCS. 
